Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAG | P20916 | 1/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HRAS | P01112 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5841001 | 0.92 | MAG (0.55) | POLBMAGLGALS8L3MBTL1HRAS | |
| SCHEMBL22204678 | 0.92 | MAG (0.55) | POLBMAGLGALS8L3MBTL1HRAS | |
| SCHEMBL5841006 | 0.92 | MAG (0.55) | POLBMAGLGALS8L3MBTL1HRAS | |
| SCHEMBL5841546 | 0.92 | MAG (0.55) | POLBMAGLGALS8L3MBTL1HRAS | |
| SCHEMBL6760495 | 0.90 | POLB (0.57) | POLBLMNAKMT2AMAGL3MBTL1 | |
| SCHEMBL542355 | 0.88 | MAG (0.58) | POLBMAGLGALS8L3MBTL1HRAS | |
| SCHEMBL16153923 | 0.88 | MAG (0.58) | POLBMAGLGALS8L3MBTL1HRAS | |
| SCHEMBL7717946 | 0.88 | MAG (0.58) | POLBMAGLGALS8L3MBTL1HRAS | |
| SCHEMBL23631539 | 0.88 | POLB (0.55) | POLBLMNAKMT2AMAGLGALS8 | |
| SCHEMBL542353 | 0.88 | MAG (0.58) | POLBMAGLGALS8L3MBTL1HRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346816-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTION | THERAPEUTIKOS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346816-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTION | THERAPEUTIKOS, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2022051575-A2 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTION | HASSAN AMEER E (US) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346816-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTION | ACE, ACE2, MAVS | POLB 493/4885LMNA 2414/4885KMT2A 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.